Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

Is U.S. Medical Device Development In Trouble ?

August 21, 2009

New leaders at FDA could slow device approvals | login.newsedge.com

There are several forces at work that could adversely affect medical device innovation and, ultimately, availability of medical devices to patients. The latest developments at the Food And Drug Administration suggest that device approvals will get more scrutiny and will be slowed down. Add to that other developments in progress in the medical device industry, and the U.S. medical device industry may well lose its once dominant position.

Will The Medical Device Safety Act of 2009 Ultimately Benefit Patients?

August 6, 2009

Senate HELP Committee Hearing on Defective Medical Devices | www.c-span.org

The Senate Health, Education, Labor and Pensions (HELP) Committee started hearings on medical device safety yesterday, in an effort to pave the way for the Medical Device Safety Act of 2009. Proponents argue that manufacturers should not be shielded from liability and that patients should have the legal right to sue manufacturers if they are harmed by a medical device. Opponents argue that the Medical Device Safety Act will make devices more costly and, ultimately, less accessible.

Recession Presents Both Challenges And Opportunities For Small MedTech Companies

February 25, 2009

Resistant in any recession? US medtech financial update and outlook | www.ey.com

With IPOs virtually eliminated and M&A activity considerably slowed, early stage medtech investors are left with few exit opportunities. Faced with continued uncertainty in the financial markets, investors remain highly selective, leaving many smaller medtech companies strapped for cash. Is this an ideal time for strategic consolidation?

Page : 11 to 3 of 3

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

This author consults with leading institutions through GLG